Kaiyue Liu, Yunyun Ji, Yiming Xie, Chengyan Wang, Jie Zhou, Ziyi Wei, Xiaoyu Wang, Xiaotong Zheng, Yao Cen, Fan Zhang, Bailing Xu
{"title":"异苯并呋喃-1(3H)- 1衍生物作为TREK-1选择性抑制剂的发现,具有体外和体内神经保护作用","authors":"Kaiyue Liu, Yunyun Ji, Yiming Xie, Chengyan Wang, Jie Zhou, Ziyi Wei, Xiaoyu Wang, Xiaotong Zheng, Yao Cen, Fan Zhang, Bailing Xu","doi":"10.1021/acs.jmedchem.4c03146","DOIUrl":null,"url":null,"abstract":"TREK-1 regulates neuronal excitability and neuronal cell apoptosis, and inhibition of TREK-1 is a potential strategy to prevent cell death and achieve neuroprotection in an ischemic stroke. In this work, a series of novel isobenzofuran-1(3<i>H</i>)-one derivatives were designed and synthesized as TREK-1 inhibitors, and extensive structure–activity relationships led to the discovery of potent and selective TREK-1 inhibitors having IC<sub>50</sub> values of a low micromolar level. Among them, <b>Cpd8l</b> potently and selectively inhibited TREK-1 (IC<sub>50</sub> = 0.81 μM, selectivity >30 fold over other K<sup>+</sup>, Na<sup>+</sup>, and TRP channels). <b>Cpd8l</b> remarkably reduced the neuron death in the OGD/R-induced cortical neuronal injury model, while adenovirus silencing TREK-1 reduced its neuroprotective effect. Furthermore, <b>Cpd8l</b> could effectively ameliorate brain injury in MCAO/R model mice. Collectively, this work demonstrates that <b>Cpd8l</b> may serve as a novel lead compound to develop a highly potent and selective TREK-1 inhibitor for ischemic stroke treatment.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"67 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of Isobenzofuran-1(3H)-one Derivatives as Selective TREK-1 Inhibitors with In Vitro and In Vivo Neuroprotective Effects\",\"authors\":\"Kaiyue Liu, Yunyun Ji, Yiming Xie, Chengyan Wang, Jie Zhou, Ziyi Wei, Xiaoyu Wang, Xiaotong Zheng, Yao Cen, Fan Zhang, Bailing Xu\",\"doi\":\"10.1021/acs.jmedchem.4c03146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"TREK-1 regulates neuronal excitability and neuronal cell apoptosis, and inhibition of TREK-1 is a potential strategy to prevent cell death and achieve neuroprotection in an ischemic stroke. In this work, a series of novel isobenzofuran-1(3<i>H</i>)-one derivatives were designed and synthesized as TREK-1 inhibitors, and extensive structure–activity relationships led to the discovery of potent and selective TREK-1 inhibitors having IC<sub>50</sub> values of a low micromolar level. Among them, <b>Cpd8l</b> potently and selectively inhibited TREK-1 (IC<sub>50</sub> = 0.81 μM, selectivity >30 fold over other K<sup>+</sup>, Na<sup>+</sup>, and TRP channels). <b>Cpd8l</b> remarkably reduced the neuron death in the OGD/R-induced cortical neuronal injury model, while adenovirus silencing TREK-1 reduced its neuroprotective effect. Furthermore, <b>Cpd8l</b> could effectively ameliorate brain injury in MCAO/R model mice. Collectively, this work demonstrates that <b>Cpd8l</b> may serve as a novel lead compound to develop a highly potent and selective TREK-1 inhibitor for ischemic stroke treatment.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"67 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.4c03146\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c03146","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Discovery of Isobenzofuran-1(3H)-one Derivatives as Selective TREK-1 Inhibitors with In Vitro and In Vivo Neuroprotective Effects
TREK-1 regulates neuronal excitability and neuronal cell apoptosis, and inhibition of TREK-1 is a potential strategy to prevent cell death and achieve neuroprotection in an ischemic stroke. In this work, a series of novel isobenzofuran-1(3H)-one derivatives were designed and synthesized as TREK-1 inhibitors, and extensive structure–activity relationships led to the discovery of potent and selective TREK-1 inhibitors having IC50 values of a low micromolar level. Among them, Cpd8l potently and selectively inhibited TREK-1 (IC50 = 0.81 μM, selectivity >30 fold over other K+, Na+, and TRP channels). Cpd8l remarkably reduced the neuron death in the OGD/R-induced cortical neuronal injury model, while adenovirus silencing TREK-1 reduced its neuroprotective effect. Furthermore, Cpd8l could effectively ameliorate brain injury in MCAO/R model mice. Collectively, this work demonstrates that Cpd8l may serve as a novel lead compound to develop a highly potent and selective TREK-1 inhibitor for ischemic stroke treatment.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.